Orthopedia (KIDS) Stock News

OrthoPediatrics (NASDAQ: KIDS) reported third quarter 2025 results for the period ended September 30, 2025, with total revenue $61.2M (up 12% YoY) and adjusted EBITDA $6.2M (up 56% YoY).

U.S. revenue was $48.7M (14% increase) and international revenue was $12.5M (6% increase). Revenue excluding 7D capital sales was $60.7M (up 17% YoY). Trauma & Deformity revenue rose 17% to $44.1M; Scoliosis revenue rose 4% to $16.3M.

GAAP diluted loss per share was $0.50; non-GAAP diluted loss per share was $0.24. Free cash flow usage improved to $3.4M (Q3 2024: $11.6M). Cash and equivalents were $59.8M as of Sept 30, 2025. Company updated full-year 2025 revenue guidance to $233.5M–$234.5M and reiterated adjusted EBITDA target of $15M–$17M.

OrthoPediatrics (Nasdaq: KIDS) announced FDA approval of the 3P Pediatric Plating Platform Small-Mini System on October 28, 2025, the company’s 6th FDA approval in 2025. The system is a variable-angle locking plate-and-screw solution for pediatric trauma and deformity surgeries with procedure-specific and utility plates in 2.0mm, 2.4mm, 2.7mm, and 3.5mm sizes.

Features include specialized instruments, streamlined tray layouts, and color-coding to enhance operating room efficiency. The Small-Mini System follows the 3P Hip System and is slated for a limited market release in early 2026.

OrthoPediatrics (Nasdaq: KIDS) will release its third quarter 2025 financial results on October 28, 2025 after market close. The company will host a conference call on October 28, 2025 at 4:30 p.m. ET to discuss results.

Investors can access a live and archived webcast via the company website on the Investors page in the Events & Presentations section. The webcast replay will be available for at least 90 days after the event.

OrthoPediatrics (Nasdaq: KIDS) reported preliminary unaudited Q3 2025 net revenue of $61.2M, up 12% year-over-year, and helped over 37,100 children in the quarter, bringing lifetime patients to ~1.3M. Domestic revenue was ~$48.7M (+14%) and international ~$12.5M (+6%). Excluding 7D capital sales, Q3 revenue was ~$60.7M (+17%).

Full-year 2025 revenue guidance was revised to $233.5M–$234.5M (14%–15% growth), down from $237.0M–$242.0M, while adjusted EBITDA guidance of $15M–$17M and $15.0M set deployment expectation were reiterated. The company cited delayed 7D capital and Latin/South America orders as timing headwinds.

OrthoPediatrics (NASDAQ: KIDS) has successfully completed the first U.S. surgical procedures using its VerteGlide Spinal Growth Guidance System, a breakthrough treatment for Early Onset Scoliosis (EOS). The procedures were performed by Dr. Richard McCarthy and Dr. Kent Walker in Louisville, Kentucky.

The VerteGlide system, part of OrthoPediatrics' Scoliosis product suite, represents an innovative solution for complex spinal pathology in early onset scoliosis patients. The technology, which utilizes Shilla™ technology licensed from Medtronic, will be featured at the 60th Annual Meeting of the Scoliosis Research Society and the 19th International Congress on Early Onset Scoliosis later this year.

OrthoPediatrics (NASDAQ: KIDS) has announced a new distribution partnership with MY01 Inc. to expand access to MY01's Continuous Perfusion Sensing Technology (CPST) Platform for children and adolescents. The partnership focuses on addressing acute compartment syndrome, a time-sensitive emergency condition that particularly affects children with orthopedic traumatic injuries.

The collaboration combines MY01's innovative technology with OrthoPediatrics' dedicated pediatric sales force and medical education resources. This partnership aims to provide clinicians with better tools and training for diagnosing and treating compartment syndrome in pediatric patients, who often struggle to communicate symptoms effectively.

OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, has appointed Kelly Fischer to its Board of Directors effective August 8, 2025. Fischer, currently serving as Senior Vice President and CFO of Cook Medical, brings over two decades of financial and operational experience in the medical device industry.

The appointment coincides with the retirement of Terry Schlotterback, who served the company for over fifteen years as Director and Chairman of the Board. Fischer, with her background as an Audit Manager at Ernst & Young and her leadership at Cook Medical, aims to support OrthoPediatrics' strategy of market expansion and technology advancement in pediatric orthopedic care.

OrthoPediatrics (NASDAQ:KIDS) reported strong Q2 2025 financial results, achieving a record-breaking quarterly revenue of $61.1 million, up 16% year-over-year. The company demonstrated robust growth with domestic revenue increasing 17% and international revenue rising 12%. Adjusted EBITDA grew significantly by 58% to $4.1 million.

Key performance highlights include worldwide Trauma & Deformity revenue growth of 10% and Scoliosis revenue surge of 35%. The company expanded its Specialty Bracing Division with new clinics and entered Ireland, marking its first international operation. OrthoPediatrics has increased its full-year 2025 revenue guidance to $237.0-$242.0 million, projecting 16-18% growth, and expects to achieve positive free cash flow by Q4 2025.

OrthoPediatrics (NASDAQ: KIDS) announced significant expansion of its Specialty Bracing (OPSB) division through multiple new clinics and territory entries. The company has established its first California clinic in Los Angeles, opened a new facility in Dayton Children's Hospital, and expanded into the Denver, Colorado territory.

Through Acquihire opportunities, OPSB added multiple locations in New York City within major Children's Hospital centers and entered its first international market in Ireland. The Irish expansion complements OrthoPediatrics' existing implant business presence and creates opportunities for further European expansion.